1. Market Research
  2. > Nonhematologic Malignancy - Pipeline Review, H2 2013

Nonhematologic Malignancy - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 43 pages

Nonhematologic Malignancy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nonhematologic Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nonhematologic Malignancy. Nonhematologic Malignancy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nonhematologic Malignancy.
- A review of the Nonhematologic Malignancy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nonhematologic Malignancy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Nonhematologic Malignancy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Nonhematologic Malignancy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Nonhematologic Malignancy - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nonhematologic Malignancy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Nonhematologic Malignancy 7
Nonhematologic Malignancy Therapeutics under Development by Companies 9
Early Clinical Stage Products 10
Comparative Analysis 10
Nonhematologic Malignancy Therapeutics - Products under Development by Companies 11
Companies Involved in Nonhematologic Malignancy Therapeutics Development 12
Boehringer Ingelheim GmbH 12
Millennium Pharmaceuticals, Inc. 13
Astellas Pharma Inc. 14
Celgene Corporation 15
Nonhematologic Malignancy - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
ixazomib citrate - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
pevonedistat - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
sirolimus albumin-bound - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
MLN-0128 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
TAK-733 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
MLN-1117 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
BI-853520 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
VS-4718 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
ASP-9853 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Nonhematologic Malignancy Therapeutics - Drug Profile Updates 34
Nonhematologic Malignancy Therapeutics - Discontinued Products 40
Nonhematologic Malignancy Therapeutics - Dormant Products 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43



List of Tables

Number of Products Under Development for Nonhematologic Malignancy, H2 2013 7
Products under Development for Nonhematologic Malignancy - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Clinical Stage Development, H2 2013 10
Products under Development by Companies, H2 2013 11
Boehringer Ingelheim GmbH, H2 2013 12
Millennium Pharmaceuticals, Inc., H2 2013 13
Astellas Pharma Inc., H2 2013 14
Celgene Corporation, H2 2013 15
Assessment by Monotherapy Products, H2 2013 16
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Stage and Molecule Type, H2 2013 20
Nonhematologic Malignancy Therapeutics - Drug Profile Updates 34
Nonhematologic Malignancy Therapeutics - Discontinued Products 40
Nonhematologic Malignancy Therapeutics - Dormant Products 41



List of Figures

Number of Products under Development for Nonhematologic Malignancy, H2 2013 7
Products under Development for Nonhematologic Malignancy - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Early Clinical Stage Products, H2 2013 10
Assessment by Monotherapy Products, H2 2013 16
Assessment by Route of Administration, H2 2013 17
Assessment by Stage and Route of Administration, H2 2013 18
Assessment by Molecule Type, H2 2013 19
Assessment by Stage and Molecule Type, H2 2013 20



Companies Mentioned

Boehringer Ingelheim GmbH
Millennium Pharmaceuticals, Inc.
Astellas Pharma Inc.
Celgene Corporation

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.